These collectively suggest that dual inhibition of both mTOR complexes is essential in targeting the PI3K/AKT/mTOR axis in GBM as opposed to only targeting mTORC1 which could result in compensatory activation of mTORC2 and hence limited clinical efficacy. The gene discussed is AKT1; the disease is glioblastoma.